adaptor molecule termed SHC binds to and is phosphorylated by the activated EGFR (Pelicci et al., 1992) . The Intracellular tyrosine kinases link the G proteintyrosine-phosphorylated and membrane-localized SHC coupled m1 muscarinic acetylcholine receptor protein then serves as a binding site for other proteins (mAChR) to multiple cellular responses. However, the which ultimately activate the Ras/MAP kinase signaling mechanisms by which m1 mAChRs stimulate tyrosine cascade and other effectors (Honegger et al., 1987; kinase activity and the identity of the kinases within Moolenaar et al., 1988; Buday and Downward, 1993) . particular signaling pathways remain largely unknown.
Introduction
homology (PH) domain-containing or Src family tyrosine kinase (Tsukada et al., 1994; Luttrell et al., 1997) . AlternatTyrosine kinases are important components of signaling ively, other types of GPCRs may activate intracellular pathways that couple cell surface receptors to the regulatyrosine kinases and the Ras pathway indirectly by contion of many cellular activities including gene expression, trolling the level of second messenger molecules (Zachary proliferation, synaptic organization and ion channel moduet al., 1992; Taniguchi et al., 1993; Chen et al., 1994; lation. Although the importance of receptor tyrosine Lev et al., 1995; Simonson et al., 1996) . Interestingly, kinases (RTKs) in growth factor signaling has been recogthere is recent evidence that the EGFR also plays a role nized for some time (Chen et al., 1987) , more recent in mitogenic signaling through thrombin, endothelin and studies have shown that other classes of receptors, includlysophosphatidic acid receptors (Daub et al., 1996) . In ing cytokine, integrin, antigen and G protein-coupled this case, pharmacological inactivation of the EGFR kinase receptors (GPCRs), also utilize tyrosine kinases to transactivity decreases the ability of these GPCRs to induce duce intracellular signals  transcription of the c-fos gene or stimulate DNA synthesis. Aoki et al., 1994; August et al., 1994; Chen et al., 1994;  The muscarinic acetylcholine receptor (mAChR) family Ihle, 1994) . Unlike the RTKs, these receptor families lack consists of five related subtypes (m1-5) that are highly intrinsic kinase activity and must recruit and activate expressed in the central and peripheral nervous systems. cytosolic proteins such as the JAK (Stahl and Yancopoulos, The m1, m3 and m5 subtypes couple to G αq type G 1993; Ihle, 1994) , FAK proteins to stimulate phospholipase C (PLC) activity and and Src family tyrosine kinases (Clark and Brugge, 1993) .
thus cause the activation of protein kinase C (PKC) and Studies of the epidermal growth factor receptor (EGFR) the release of Ca 2ϩ from intracellular stores (Lechleiter have contributed many insights into the mechanisms by et al., 1990a,b; Berstein et al., 1992) . In contrast, m2 and which RTKs transduce proliferative signals. Activation of EGFRs typically begins with ligand-induced receptor m4 mAChRs mediate the inhibition of adenylyl cyclase activity and activation of inward rectifier K ϩ channels through G βγ subunits derived from G αi and G αo type G proteins (Peralta et al., 1988; Reuveny et al., 1994; Kunkel and Peralta, 1995) . Muscarinic receptors have been implicated in complex processes ranging from learning and memory to several CNS disorders such as Alzheimer's and Parkinson's disease (Nathanson, 1987; Taylor, 1990; Nitsch et al., 1992) . At the cellular level, mAChRs stimulate tyrosine kinases to regulate such responses as release of the secreted amyloid precursor protein (Slack et al., 1995) , activation of the Ras pathway (Crespo et al., 1994) and modulation of delayed rectifier K ϩ channel activity (Huang et al., 1993) . However, as is true for several other classes of GPCRs, the mechanisms by which mAChRs stimulate particular tyrosine kinases are not well defined. Through studies in stable transfected human 293 cells, that reveal a novel function of the m1 mAChR-stimulated EGFR transactivation pathway, namely modulation of the voltage-gated K ϩ channel termed Kv1.2 (Paulmichl et al., we also observed a higher molecular weight band of~175 kDa that co-immunoprecipitated with SHC and became 1991; Huang et al., 1993; Morielli et al., 1995) . Taken together, this study identifies the EGFR as a target of m1 tyrosine phosphorylated in response to either EGF or carbachol treatment. Since p52 SHC was identified originmAChR signaling and demonstrates a new role for the EGFR in neurotransmitter receptor signaling.
ally as a substrate for the 175 kDa EGFR, we re-probed the same nitrocellulose filter with an anti-EGFR antibody and found that the 175 kDa band became labeled ( Figure   Results 2A). Thus, activation of the m1 mAChR induces tyrosine phosphorylation of the EGFR. In addition, pre-treatment
EGFR activation by the m1 mAChR
To assess the ability of m1 mAChRs to stimulate tyrosine of cells with a specific inhibitor of the EGFR kinase activity, tyrophostin AG1478, blocked both the EGF-and kinase activity, we treated stable transfected 293 cells with carbachol, a stable muscarinic agonist, and analyzed carbachol-stimulated tyrosine phosphorylation of SHC, as well as the SHC-associated 175 kDa protein identified as cellular lysates by immunoblotting with an anti-phosphotyrosine monoclonal antibody (4G10). Carbachol treatment the EGFR (Figure 2A ; see below).
To explore the specificity of this transactivation pathway, resulted in a clear increase in the tyrosine phosphorylation of several proteins ranging in mol. wt from 45 to 175 kDa we tested whether another endogenous RTK, the insulin receptor, also becomes tyrosine phosphorylated via m1 (Figure 1 ). Treatment with atropine, a muscarinic antagonist, completely blocked this effect. The striking induction mAChR signaling. To this end, we analyzed the phosphotyrosine content of immunoprecipitated insulin receptors in the phosphotyrosine state of multiple proteins following carbachol treatment strongly suggests that one or more before and after carbachol treatment. This analysis demonstrated that carbachol does not induce an increase in the tyrosine kinases are activated by m1 mAChRs, although alterations in tyrosine phosphatase activity are also tyrosine phosphorylation of insulin receptors and suggests that the m1 mAChR transactivation pathway exhibits some possible.
Since the SHC adaptor protein is an important comdegree of specificity among different RTKs ( Figure 2B ). To establish further that the carbachol-induced increase ponent of the pathways linking RTKs and some GPCRs to activation of the Ras cascade (Crespo et al., 1994;  in the phosphotyrosine content of EGFRs reflects activation of the intrinsic kinase domain, we conducted two Pawson, 1995; van Biesen et al., 1995) , we next examined whether the p52 isoform of SHC becomes tyrosine phostypes of experiments. First, we tested whether tyrophostin AG1478 could affect the ability of m1 mAChRs to phorylated in our system. We immunoprecipitated the SHC protein from cells that had been treated with EGF stimulate tyrosine phosphorylation of the EGFR. Previous reports indicate that tyrophostin AG1478 acts as a specific (to activate endogenous EGFRs) or carbachol and analyzed the immunoprecipitates using the 4G10 antibody. As inhibitor of EGFR kinase activity, and has no significant effect on other tyrosine kinases tested (Levitzki and Gazit, expected, the control treatment with EGF caused a robust increase in the phosphotyrosine content of p52 SHC 1995). To determine the efficacy and specificity of AG1478 in our system, we analyzed the effect of the drug on ( Figure 2A) . Similarly, carbachol evoked a potent increase in tyrosine-phosphorylated SHC (Figure 2A ). Interestingly, EGF-or carbachol-induced tyrosine phosphorylation of of the insulin receptor by its ligand ( Figure 3B ). Therefore, experiments with AG1478 indicate that the carbacholinduced increase in tyrosine phosphorylation most likely results from activation of the EGFR's intrinsic kinase domain, rather than through a transphosphorylation mechanism involving a distinct tyrosine kinase. To test this interpretation, we also conducted immunoblotting experiments using a monoclonal antibody that recognizes specifically the kinase-activated conformation of the EGFR (Emlet et al., 1997) . Cells were treated with carbachol or EGF and the lysates were immunoblotted and probed with the activation-specific antibody ( Figure 3C ). This antibody clearly detected the EGFRs obtained from carbachol-and EGF-treated cells. Taken together, these findings establish that the m1 mAChR-mediated pathway results in activation of the intrinsic kinase domain of the EGFR.
EGF-independent EGFR dimerization
Since previous studies have shown that dimerization of EGFRs is a prerequisite for EGF-induced activation, we asked whether the m1 mAChR-induced transactivation pathway also involves the formation of EGFR dimers. The compound bis(sulfosuccinimidyl)suberate (BS 3 ) is an effective EGFR cross-linking reagent in intact living cells (Sorkin and Carpenter, 1991) . To determine if EGFR dimers form in response to m1 mAChR activation, BS 3 we investigated whether carbachol induced the release of EGF from these cells. Culture supernatants from EGF-or carbachol-treated cells were collected, concentrated and the EGFR. The phosphotyrosine content of EGFRs subjected to immunoblot analysis with an anti-EGF antiimmunoprecipitated from cells pre-treated with 250 nM body. We previously found that 20 ng of EGF was required AG1478 prior to EGF or carbachol addition was significto stimulate the phosphotyrosine content of EGFRs sigantly less than from cells exposed to EGF or carbachol nificantly under the conditions used for all experiments alone ( Figure 3A ). To confirm the selectivity of AG1478 described in this study (not shown). However, we were in our system, we also tested whether the carbacholunable to detect the presence of EGF in the supernatants dependent activation of two distinct types of cytoplasmic collected from carbachol-treated cells even though the tyrosine kinases, p60 Src and p125 FAK, or activation of anti-EGF antibody was able to detect ഛ10 ng of EGF in insulin receptors by insulin, was affected by the drug.
this assay ( Figure 4B ). Therefore, we conclude that the These experiments demonstrated that cells pre-treated with m1 mAChR probably does not induce EGFR dimerization 1 μM AG1478 failed to block carbachol-induced tyrosine phosphorylation of the Src and FAK kinases, or activation through an autocrine mechanism.
EGFR transactivation is a PKC-dependent, to determine if PKC lies in the pathway between m1
Ca 2⍣ -insensitive response mAChR stimulation and EGFR transactivation, we treated Activation of PLCβ by m1 mAChRs leads to the activation cells with the specific PKC inhibitor, GF109203X (Toullec of the serine/threonine kinase family termed protein kinase et al., 1991) , for 20 min prior to addition of carbachol. C (PKC) and the release of Ca 2ϩ from intracellular stores Treatment with GF109203X potently inhibited the sub- (Berridge, 1993) . To test the role of PKC in the m1 sequent carbachol-induced tyrosine phosphorylation of the mAChR-mediated transactivation pathway, we treated 293 EGFR in these cells ( Figure 5 ). Thus, PKC activation cells with the PKC activator, phorbol 12-myristate 13-appears to be both sufficient and necessary for m1 mAChRacetate (PMA). This treatment dramatically increased the induced EGFR activation. phosphotyrosine content of immunoprecipitated EGFRs
Since carbachol induces a large increase in cytoplasmic ( Figure 5 ). Therefore, activation of PKC is sufficient to Ca 2ϩ in 293 cells expressing m1 mAChRs, we asked cause tyrosine phosphorylation of the EGFR. However, whether elevated Ca 2ϩ also contributes to the transactivation of EGFRs. To this end, we applied the Ca 2ϩ ionophore, A23187 (1 μM, 10 min), and again analyzed the phosphotyrosine content of the immunoprecipitated EGFR. A23187 treatment did not induce an increase in the phosphotyrosine content of EGFRs ( Figure 5 ) even though direct Ca 2ϩ imaging analysis of these cells confirmed that the ionophore treatment evoked a rapid and dramatic elevation in intracellular Ca 2ϩ (not shown). Consistent with this result, cells pre-treated with the Ca 2ϩ chelators EGTA and EDTA prior to carbachol treatment also responded normally ( Figure 5 ; see Materials and methods for additional details). Therefore, increases in intracellular Ca 2ϩ concentration due to Ca 2ϩ influx do not appear to be an important signal for the m1 mAChRinduced EGFR transactivation mechanism. EGF should also cause an AG1478-sensitive suppression of Kv1.2 activity. Consistent with this interpretation, application of EGF caused a strong suppression of the Transactivated EGFRs contribute to K ⍣ channel modulation Kv1.2 current in these cells ( Figure 6D ). Moreover, the EGF-induced response was blocked completely by preActivation of the EGFR typically is associated with mitogenic responses (Ullrich and Schlessinger, 1990 ; Daub treatment with AG1478 ( Figure 6D ). Therefore, these electrophysiological experiments provide the first demonet al., 1996). However, previous research in 293 cells has shown that m1 mAChRs cause a suppression of the ionic stration that transactivated EGFRs are an important component in a pathway linking a G protein-coupled receptor current carried by the delayed rectifier K ϩ channel, termed Kv1.2, through a tyrosine kinase-dependent mechanism to modulation of a defined ion channel. (Huang et al., 1993; Lev et al., 1995) . Since the experiments described above suggest that transactivated EGFRs Discussion may account for a significant fraction of m1 mAChRstimulated tyrosine kinase activity in these cells, we
The importance of RTKs in growth factor signaling and oncogenic transformation has been clear for some time. tested the possibility that the transactivated receptors may contribute to modulation of the Kv1.2 channel. To test However, only recently have tyrosine kinases been recognized as important components of particular GPCR sigthis idea, we again used the specific EGFR kinase inhibitor tyrophostin AG1478 with the expectation that if m1 naling pathways (Huang et al., 1993; Crespo et al., 1994; van Biesen et al., 1995; Chen et al., 1996) . The studies mAChR-induced channel suppression involves EGFR transactivation, then such suppression should be blocked described here demonstrate that transactivated EGFRs can play an important role in m1 mAChR-mediated signaling at least in part by pre-treatment with AG1478. Prior to any treatment, Kv1.2 channels expressed in 293 cells both at the membrane and within the cell. In particular, these studies indicate a novel role for transactivated EGFRs generated an outward K ϩ current typical of delayed rectifiers ( Figure 6A, left panel) . This channel activity in the modulation of ion channel activity by GPCRs. The results of biochemical and pharmacological experi-PKC, participates in the transactivation mechanism. Activation of PKC by phorbol esters caused a strong ments provide several insights into the mechanism of EGFR transactivation by m1 mAChRs. Immunoprecipitincrease in the abundance of tyrosine-phosphorylated EGFRs, while application of a PKC inhibitor, GF109203X, ation studies revealed that the abundance of tyrosinephosphorylated EGFR was increased significantly by completely blocked EGFR activation by carbachol. In contrast, EGFR transactivation does not require Ca 2ϩ -carbachol treatment. Since the EGFR kinase inhibitor AG1478 blocked both EGF-and carbachol-induced dependent signals, as demonstrated by the inability of the Ca 2ϩ ionophore, A23187, to induce EGFR phosphorylation increases in EGFR phosphotyrosine content, we conclude that the carbachol-induced increase also represents EGFR or Ca 2ϩ chelators to block carbachol-mediated transactivation. There is recent evidence in other cell types that Ca 2ϩ autophosphorylation via activation of its intrinsic tyrosine kinase domain. Activation of the EGFR was also supported influx through voltage-gated channels can be sufficient to cause tyrosine phosphorylation of the EGFR (Rosen and by immunoblotting analysis with an antibody that specifically recognized the active conformation of EGFRs Greenberg, 1996) . However, we find that transactivation by the m1 mAChR in human 293 cells involves primarily isolated from carbachol-treated cells. Previous studies have shown that stimulation of the tyrosine kinase domain PKC-dependent signals. It is possible that PKC directly phosphorylates the EGFR, although numerous studies have of the EGFR follows a second order reaction rate constant with respect to the EGFR concentration, indicating that shown that such phosphorylation is associated with downregulation of EGF-dependent receptor activation (Cochet dimerization of monomeric EGFRs is essential for full activation by EGF (reviewed in Schlessinger, 1988; Ullrich et al., 1984; Downward et al., 1985; Fearn and King, 1985) . Alternatively, PKC-stimulated signals may lead to and Schlessinger, 1990; Canals, 1992) . Our cross-linking results present the first demonstration that EGFR dimers the activation of intracellular tyrosine kinases which in turn phosphorylate the EGFR. We note that the ability of are also formed as a consequence of m1 mAChR activation. Furthermore, we were unable to detect the presence of m1 mAChRs to activate the Src and FAK tyrosine kinases in the absence of carbachol-induced EGFR tyrosine EGF in carbachol-treated culture supernatants, indicating that carbachol does not induce an autocrine release of phosphorylation (i.e. following AG1478 treatment) indicates that neither of these tyrosine kinases directly phos-EGF. Thus, carbachol binding to the m1 mAChR generates an intracellular signaling cascade that leads to EGFphorylate the EGFR in our system. Recent crystal structures of the cytoplasmic tyrosine independent receptor dimerization and catalytic activation.
We conducted several experiments to investigate which kinase domains of the insulin and fibroblast growth factor receptors have provided important information regarding intracellular signals may play a role in the EGFR transactivation pathway. Since m1 mAChRs are strong activthe mechanism by which these RTKs are activated (Hubbard et al., 1994; Mohammadi et al., 1996) . While ators of PLCβ, we tested the importance of PKC and intracellular Ca 2ϩ release in this process. Our data indicate similar structural information is not yet available for the EGFR, numerous biochemical studies have shown that that only one of the two PLC signaling branches, namely insulin receptor); Santa Cruz (anti-Src); and Transduction Laboratories dimerization of the monomeric receptor by EGF must (anti-FAK and activation-specific anti-EGFR). Protein G and protein Aoccur in order to induce its tyrosine kinase activity (Yarden Sepharose beads were purchased from Sigma and Pharmacia, respect- and Schlessinger, 1987; Ullrich and Schlessinger, 1990;  ively. The protein kinase C activator, PMA, and the Ca 2ϩ ionophore, Schlessinger and Ullrich, 1992) . Our findings provide A23187, were purchased from Sigma. The protein kinase C inhibitor, GF109203X, was purchased from Research Biochemical International.
evidence that EGFR dimerization and activation can
The EGFR kinase inhibitor, tyrophostin AG1478, was purchased from occur in the absence of EGF. Whether EGF-independent Calbiochem. The EGFR cross-linking reagent, BS 3 , was purchased dimerization of the receptor is responsible for kinase from Pierce. activation, or vice versa, remains unknown. It is possible that carbachol regulates an intracellular signaling pathway
Cell culture
Human embryonic kidney 293 cells were transfected by the calcium that leads to an alteration in proteins that may associate phosphate method. Stable cell lines expressing both the m1 mAChR and with the EGFR or perhaps cause a covalent modification Kv1.2 proteins were obtained as described by Peralta et al. (1988) . SHC, of the EGFR cytoplasmic domain. This may induce a EGFRs, insulin receptors, Src and FAK proteins are endogenously conformational change which in turn causes dimerization expressed by these cells. The 293 cells were grown in Dulbecco's of the EGFR resulting in kinase activation. Alternatively, modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and streptomycin, 2 mM L-glutamine, m1 mAChR-induced dimerization of the EGFR may not and selected with 500 μg/ml of G418. For intracellular Ca 2ϩ measurebe essential for activation, but simply be a secondary ments, the cells were loaded with fura-2 AM for 1 h in the same medium effect. For example, m1 mAChR-generated signals may and changes in Ca 2ϩ concentration were determined by ratiometric cause conformational changes in the EGFR monomer that analysis as described previously (Dell'Acqua et al., 1993) . Addition of lead directly to kinase activation. In this case, dimerization domain is normally responsible for stabilizing EGFCells were lysed in a modified RIPA buffer containing Tris-HCl (50 mM, induced dimers (Hurwitz et al., 1991; Lax et al., 1991) , plasmic EGFR kinase domain may also form dimers and 1 mM), leupeptin (10 μg/ml), aprotinin (10 μg/ml), sodium orthovanadate higher aggregates (Murali et al., 1996) . A full kinetic suppression, indicating that transactivated EGFRs are a significant component in a pathway by which m1 mAChRs EGFR cross-linking regulate the Kv1.2 channel. We note, however, that the 293 cells expressing the m1 mAChR were grown to confluency in a 60 mm dish. Subsequently, cells were serum starved in DMEM containing transactivation pathway is not entirely responsible for 0.1% FBS for 14 h and treated with either EGF (1 μg/ml) for 15 min m1 mAChR-mediated channel modulation, since AG1478 at 37°C or carbachol (1 mM) for 15 min at 37°C. Cells were washed does not completely block the entire carbachol response.
with ice-cold phosphate-buffered saline (PBS) and the cross-linking Consistent with this observation, Ca 2ϩ -activated tyrosine reagent BS 3 (3 mM) was added and incubated for 20 min at 4°C. To kinases can also cause Kv1.2 suppression, indicating that terminate the cross-linking reaction, cells were washed with ice-cold PBS containing glycine (250 mM, pH 9.0) and incubated for 5 min at there are multiple pathways to regulate the same ion 4°C. After decanting the glycine solution, cells were washed and channel (Huang et al., 1993; Morielli et al., 1995) . For solubilized in a buffer containing Triton X-100 (1%), glycerol (10%), example, the FAK-related kinase termed PYK2 has been HEPES (50 mM, pH 7.4), sodium orthovanadate (1 mM), PMSF (1 mM), shown to be Ca 2ϩ activated and capable of mediating leupeptin (10 μg/ml) and aprotinin (10 μg/ml). The cell lysates were suppression of the Kv1.2 current (Lev et al., 1995) . In incubated for 20 min at 4°C and centrifuged at 12 000 g for 10 min to get rid of the insoluble debris. To the supernatant, 2 μg of anti-EGFR conclusion, our studies reveal a novel role for EGFRs in antibody were added (6 h, 4°C) followed by addition of protein Gthe regulation of membrane excitability and intracellular agarose beads (12 h, 4°C). The immunoprecipitates were resolved by signaling through m1 mAChRs and perhaps other G 6% SDS-PAGE, transferred to nitrocellulose and immunoblotted with protein-coupled neurotransmitter receptors.
anti-EGFR antibody.
EGF detection

Materials and methods
To detect the presence of EGF in the culture media, culture supernatant from serum-starved cells treated with EGF (50 ng/ml, 15 min at 37°C) Reagents or carbachol (1 mM, 15 min at 37°C) and untreated cells (control) Antibodies were purchased from the following vendors: Upstate Biotechnology (4G10-HRP, anti-EGFR, anti-EGF, anti-SHC and anti-β subunit were collected and concentrated in a Centricon 3 concentrator. The concentrated samples subsequently were resolved in 12% SDS-PAGE, Cochet,C., Gill,G.N., Meisenhelder,J., Cooper,J.A. and Hunter,T. (1984) 
